Every state
All fifty states and the District of Columbia, grouped by how far each has gone on ibogaine. Select a state for its timeline, bills, funding and organizations.
Last checked: October 26, 2026
Law enacted8
A law touching ibogaine or iboga is on the books.
New Hampshire
New Hampshire's HB 1772, signed 2026-07-15 and in effect since 2026-09-13, lets licensed prescribers use ibogaine for investigational use only.
Indiana
Indiana's 2025-27 budget expanded its therapeutic psilocybin research fund to include ibogaine, with $300,000 listed per fiscal year.
Colorado
Colorado enacted HB26-1325 in 2026, creating an ibogaine research pilot program within the Behavioral Health Administration.
Kentucky
Kentucky enacted SB 77 in April 2026 over the governor's veto, creating an ibogaine research fund run by the Department of Agriculture.
Tennessee
Tennessee's HOPE Treatment Act (HB 2075) became law in May 2026, authorizing ibogaine clinical-trial participation and a new oversight council.
District of Columbia
DC's Initiative 81 (2020) lists iboga-containing plants among entheogens whose enforcement is deprioritized; no ibogaine-specific 2025-2026 activity found.
Oklahoma
Oklahoma enacted HB 3834, the Breakthrough Therapy Act, in May 2026; it takes effect 2026-11-01 and authorizes state-contracted ibogaine clinical trials with no appropriation.
Louisiana
Louisiana SB 43 creates a Psychedelic-Assisted Therapy Initiative covering ibogaine at the Department of Health; effective 2026-08-01.
Research funded4
The state has appropriated money for ibogaine research or trials.
Washington
Washington funds University of Washington ibogaine research: $250,000 in the 2024 supplemental budget and a $10,000 randomized cohort study proviso in the 2025-27 budget, kept in the 2026 supplemental.
Arizona
Arizona funded a $5 million ibogaine grant; Barrow Neurological Institute received it in August 2026 for a brain injury trial.
Mississippi
Mississippi enacted HB 314 on 2026-03-26, directing the Department of Health to fund an ibogaine clinical trial consortium with $5 million.
Texas
Texas awarded $50 million to UTHealth Houston and UTMB for the IMPACT ibogaine trials after no drug company met SB 2308 requirements.
Bill introduced10
Ibogaine legislation has been introduced in a recent session.
Vermont
Vermont H.859 would create a psychedelic advisory board and contract for ibogaine clinical trials; referred to committee 2026-02-03.
Michigan
HB 6020 would create an ibogaine grant program funded with $50 million from the Michigan Opioid Healing and Recovery Fund; sent toward the House Rules Committee in June 2026.
New York
New York has four pending ibogaine bills (S1817/A1522, S4664, A9583) on research, a PTSD study and veterans grants; none enacted.
Massachusetts
A Massachusetts House-passed psychedelic clinic pilot is before economic development negotiators; advocates seek ibogaine inclusion.
Oregon
HB 4110 (2026) would have let physicians provide ibogaine from 2027; it stayed in committee and failed 2026-03-06.
Missouri
Missouri's 2026 session closed on May 15 without final passage of its ibogaine trial-grant proposals; the House passed a combined version 137-11 that stalled in the Senate.
West Virginia
West Virginia HB 4626, an ibogaine trial grant program, passed 2026-03-12 and was vetoed by Gov. Morrisey.
Maryland
Maryland's 2026 Veterans Mental Health Innovations Act (HB 1477 / SB 527) would fund ibogaine trials from the Opioid Restitution Fund; HB 1477 is marked dead.
North Carolina
North Carolina's bipartisan HEAL Act (SB 1018) would put $5.4 million toward state research grants on psychedelic therapies, ibogaine included.
Georgia
Georgia HB 1296, a veterans and first-responder pilot covering ibogaine-based therapies, passed the House 169-0 in 2026 and died in a Senate committee.
Study or task force3
A task force, working group or study covers ibogaine.
Alaska
A legislative psychedelic task force issued a final report in 2026; no ibogaine-specific bill or funding found.
Nevada
Nevada's Psychedelic Medicines Working Group examined ibogaine, a 2025 resolution (SJR 10) urged Congress to reschedule it, and a 2025 veterans' pilot bill covering ibogaine (AB 378) failed.
Ohio
Ohio's 2025 budget created an Ibogaine Treatment Study Committee, chaired by Rep. Justin Pizzulli, with a report due 2027-12-31.
No known activity26
Checked on the date shown; no ibogaine-specific activity found.
How this tracker is kept
- Each state is checked against legislature records, agency releases and published reporting, and carries the date it was last checked. Every development links to its source.
- “No known activity” means the state was checked on the date shown and no ibogaine-specific law, bill, funding or task force was found.
- The directory lists organizations and public offices with their own websites. Listing points readers to them and does not endorse them.
- This tracker is offered for education and does not constitute legal or medical advice. Ibogaine and iboga remain Schedule I substances under federal law. See the medical disclaimer.
- To share a development or request a correction, write to aloha@vitalkauai.com. For daily coverage, see Iboga Worldwide.